About GSK Biologicals
GlaxoSmithKline (GSK) – a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK is the world’s leading vaccine company, with a portfolio that helps protect people throughout life and an innovative pipeline of 15 vaccines in development. Our vaccines help prevent illnesses such as hepatitis A and B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, pneumococcal disease, influenza, shingles and meningitis. At GSK, more than 17,000 people worldwide deliver around 2 million vaccine doses per day to people in more than 160 countries. GSK’s three global R&D centres in Rixensart (Belgium), Rockville (US), and Siena (Italy) are focused on discovering and developing novel vaccines across a range of pressing public health threats, concentrating on those which offer significant improvements over existing options or tackle diseases for which no vaccines yet exist. GSK is focused on addressing the burden of AMR, preventing infections to reduce society’s dependence on antibiotics. For such purpose, GSK is actively participating in the development of innovative AMR-relevant vaccines aimed at preventing infections where target pathogens are likely to drive antibiotic use and resistance. GSK is collaborating with external experts to expand and to strengthen the evidence-base on vaccines and AMR and is supporting the expansion of economic models for vaccines that account for the value of reduced antibiotic use.
Link to website: